First Trust Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

First Trust Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-97,078	Closed	-$4.56M	–	2730
2025 Q2	$4.56M	Buy	97,078 +52,718	+119%	+$2.35M	﹤0.01%	1393
2025 Q1	$1.96M	Buy	44,360 +31,263	+239%	+$1.44M	﹤0.01%	1792
2024 Q4	$473K	Buy	13,097 +2,115	+19%	+$73.9K	﹤0.01%	2269
2024 Q3	$352K	Buy	10,982 +1,602	+17%	+$59.9K	﹤0.01%	2243
2024 Q2	$353K	Buy	9,380 +2,848	+44%	+$120K	﹤0.01%	2181
2024 Q1	$322K	Sell	6,532 -3,597	-36%	-$166K	﹤0.01%	2225
2023 Q4	$370K	Buy	+10,129	New	+$264K	﹤0.01%	2206

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

First Trust Advisors's SWTX Position: Q3 2025 in Review

First Trust Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 97,078 shares — an estimated $4.56M sold.

First Trust Advisors first reported a position in SWTX in Q4 2023 and held it in 7 quarters. The position peaked at $4.56M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

First Trust Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
First Trust Advisors sold 97,078 SpringWorks Therapeutics shares in Q3 2025, an estimated $4.56M.
First Trust Advisors first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 7 quarters.
First Trust Advisors's SpringWorks Therapeutics position peaked at $4.56M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on First Trust Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.